| 包装 | 价格(元) |
| 1mg | 电议 |
| 10mg | 电议 |
Cell lines | MCF7 human breast cancer cell line |
Preparation Method | Various concentrations of nivolumab (0, 2, 4, 8, 16, and 32 nM) and OCT4&SOX2 CTLs with an effector-target ratio of 20:1 were used to treat MCF7 BCSCs for 24 h; cell proliferation was detected busing the CCK-8 assay. |
Reaction Conditions | 0, 2, 4, 8, 16, and 32 nM; 24 h |
Applications | Nivolumab improved the cytotoxic activity of OCT4&SOX2 CTLs against MCF7 BCSCs in a dose-dependent manner by the CCK-8 assay. |
Animal models | cynomolgus macaques |
Preparation Method | In a single-dose pharmacokinetic study, cynomolgus monkeys (Macaca fascicularis) received i.v. nivolumab, 1 mg/kg (3 males and 3 females) or 10 mg/kg (3 males). |
Dosage form | 1 mg/kg or 10 mg/kg; i.v. |
Applications | Single, i.v. administration of nivolumab to cynomolgus monkeys at 1 and 10 mg/kg was well tolerated with no effects on body weight or clinical observations. |
| 文献引用 | |
| 产品描述 | Nivolumab, an anti-cancer monoclonal antibody, is a programmed death receptor-1 blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.[1] In vitro efficacy test it shown that Nivolumab bound to CHO cells expressing PD-1 with an EC50 of 1.66 nmol/L and bound to PD-1 on activated T cells with an EC50 of 0.64 nmol/L. In the meanwhile, Nivolumab can inhibit the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC50 values of 2.52 and 2.59 nmol/L, respectively. In vitro, at 1.5 ng/mL concentrations of nivolumab enhances T-cell reactivity in the presence of a T-cell receptor stimulus.[1] In vivo study it indicated that mice were treated with 50 mg/kg nivolumab, there were no changes in T3, T4, or TSH levels. After administration of 10 mg/kg and 50 mg/kg nivolumab in cynomolgus monkeys, the results shown that there were dramatically more CD8+ effector memory T cells in the 50 mg/kg group than in the 10 mg/kg and untreated groups and Naive T-cell populations were decreased in the 50 mg/kg group.[1]In vivo, Nivolumab treatment (30 mg/kg, i.p.) inhibits growth of the TNBC MDA-MB-231 cell line in hu-CB-BRGS mice.[3]BLT-NOG-EXL mice treated with either saline, 2.5, 5, or 10 mg/kg of nivolumab i.p. for 28 days, the results demonstrated a dose-dependent relationship in mortality.[4]In vivo test it suggested that anti-PD-1 treatment with Nivolumab (10 mg/kg, i.v.) diminishes morphine antinociception in wild-type mice.[5] References: |
m.cnreagent.com